Short description
(English)
|
Development of bispecific IgG antibodies that induce killing of Acute Myeloid Leukemia by the patient's own T cells. By targeting AML tumor stem cells it is aimed: 1) To treat AML patients with chemotherapy resistant tumors and 2) To prevent AML relapse by tumor stem cell therapy during remission
|
